Cargando…

500例肺癌患者首诊症状及其影响因素分析

BACKGROUND AND OBJECTIVE: As the morbidity and mortality in lung cancer keep raising, we are here to discuss the effect of clinical features especially the initial symptomon on diagnosis and follow-up treatment of newly diagnosed lung cancer patients. METHODS: The clinical features of the 500 patien...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999928/
https://www.ncbi.nlm.nih.gov/pubmed/29764592
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.05.09
_version_ 1783331558620397568
collection PubMed
description BACKGROUND AND OBJECTIVE: As the morbidity and mortality in lung cancer keep raising, we are here to discuss the effect of clinical features especially the initial symptomon on diagnosis and follow-up treatment of newly diagnosed lung cancer patients. METHODS: The clinical features of the 500 patients with lung cancer in our hospital from March, 2017 to May, 2017 were analyzed retrospectively, including the initial symptom, stage, biomarkers, pathology, etc. RESULTS: There were 266 famle (53.3%), 372 adenocarcinoma (74.4%), 285 smokers (58%), status score of most patients (98.2%) was 0-1. 58.2% (n=291) of all the patients got biomarkers test, of which epidermal growth factor receptor (EGFR) mutations was 61.2%(178/291), anaplasticlymphoma kinase (ALK) fusion gene positive was 4.1% (12/291). Smoking status, initial symptom, pathological typing, TNM staging and EGFR mutation were the main factors affecting follow-up treatment. CONCLUSION: Patients with typical symptoms have shorter diagnosis time. Smoking status, lung cancer-related symptoms, pathology, TNM staging and EGFR mutation status are the main factors that affect the follow-up treatment.
format Online
Article
Text
id pubmed-5999928
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59999282018-07-06 500例肺癌患者首诊症状及其影响因素分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: As the morbidity and mortality in lung cancer keep raising, we are here to discuss the effect of clinical features especially the initial symptomon on diagnosis and follow-up treatment of newly diagnosed lung cancer patients. METHODS: The clinical features of the 500 patients with lung cancer in our hospital from March, 2017 to May, 2017 were analyzed retrospectively, including the initial symptom, stage, biomarkers, pathology, etc. RESULTS: There were 266 famle (53.3%), 372 adenocarcinoma (74.4%), 285 smokers (58%), status score of most patients (98.2%) was 0-1. 58.2% (n=291) of all the patients got biomarkers test, of which epidermal growth factor receptor (EGFR) mutations was 61.2%(178/291), anaplasticlymphoma kinase (ALK) fusion gene positive was 4.1% (12/291). Smoking status, initial symptom, pathological typing, TNM staging and EGFR mutation were the main factors affecting follow-up treatment. CONCLUSION: Patients with typical symptoms have shorter diagnosis time. Smoking status, lung cancer-related symptoms, pathology, TNM staging and EGFR mutation status are the main factors that affect the follow-up treatment. 中国肺癌杂志编辑部 2018-05-20 /pmc/articles/PMC5999928/ /pubmed/29764592 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.05.09 Text en 版权所有©《中国肺癌杂志》编辑部2018 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
500例肺癌患者首诊症状及其影响因素分析
title 500例肺癌患者首诊症状及其影响因素分析
title_full 500例肺癌患者首诊症状及其影响因素分析
title_fullStr 500例肺癌患者首诊症状及其影响因素分析
title_full_unstemmed 500例肺癌患者首诊症状及其影响因素分析
title_short 500例肺癌患者首诊症状及其影响因素分析
title_sort 500例肺癌患者首诊症状及其影响因素分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999928/
https://www.ncbi.nlm.nih.gov/pubmed/29764592
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.05.09
work_keys_str_mv AT 500lìfèiáihuànzhěshǒuzhěnzhèngzhuàngjíqíyǐngxiǎngyīnsùfēnxī
AT 500lìfèiáihuànzhěshǒuzhěnzhèngzhuàngjíqíyǐngxiǎngyīnsùfēnxī
AT 500lìfèiáihuànzhěshǒuzhěnzhèngzhuàngjíqíyǐngxiǎngyīnsùfēnxī
AT 500lìfèiáihuànzhěshǒuzhěnzhèngzhuàngjíqíyǐngxiǎngyīnsùfēnxī